Global Structural Heart Devices Market

Structural Heart Devices Market Size, Share, Growth Analysis, By Product(Heart Valve Devices (Transcatheter Heart Valves, Surgical Heart Valves (Tissue Heart Valves, Mechanical Heart Valves)), Occluders & Delivery Systems), By Procedure(Replacement Procedures (TAVR Procedures, Savr Procedures), Repair Procedures (Closure Procedures, Annuloplasty), By Region - Industry Forecast 2025-2032


Report ID: SQMIG35G2184 | Region: Global | Published Date: October, 2024
Pages: 157 | Tables: 34 | Figures: 74

Structural Heart Devices Market Insights

Structural Heart Devices Market size was valued at USD 11.97 Billion in 2023 and is poised to grow from USD 13.1 Billion in 2024 to USD 26.89 Billion by 2032, growing at a CAGR of 9.4% during the forecast period (2025-2032).

High prevalence of targeted diseases is the key driver of the structural heart devices market growth. About 60 million people in the U.S. have systemic flaws at their heart. This is 20-25% of the country’s adult population. This shows how great these devices are in preventing cardiac system defects. Treatment of systemic heart disease (SHD) includes a wide range of percutaneous therapies for patients with acquired heart disease and congenital heart disease (CHD) involving the heart chamber, proximal great vessels, and myocardial infarction. 

Costs in the U.S. are expected to be $1.5 billion will be much better in the coming years, so procedures like TAVR (Transcatheter Aortic Valve Replacement) will become more affordable as the target population ages and pays for treatment at the Centers for Medicare and Medicaid Services (CMS). It reduces healthcare costs, thus encouraging more people to opt for these treatments. This is a positive factor for a positive effect on procedures such as left atrial appendicectomy (LAAC), which is useful for reducing the risk of stroke. Industry players invest heavily in R&D programs to come up with effective products and compete in the structural heart devices industry. For example, Medtronic, Boston Scientific, Abbott and Edwards Lifesciences represented several organizations and released updates on their heart offerings at the 34th Transcatheter Cardiac Therapy (TCT) Conference in September 2022 in Boston.

US Structural Heart Devices Market is poised to grow at a sustainable CAGR for the next forecast year.

$5,300
BUY NOW GET FREE SAMPLE
Want to customize this report?

Our industry expert will work with you to provide you with customized data in a short amount of time.

REQUEST FREE CUSTOMIZATION

FAQs

Structural Heart Devices Market size was valued at USD 10.97 billion in 2022 and is poised to grow from USD 11.97 billion in 2023 to USD 24.58 billion by 2031, growing at a CAGR of 9.4% in the forecast period (2024-2031)

The competitive environment in the market is characterized by leading medical device manufacturers and new start-up companies specializing in advanced, simple solutions for cardiac surgery. Technological advances, increasing clinical research, and strategic partnerships focused on improving patient outcomes drive the growth of this market. Companies are actively pursuing FDA approvals and expanding their services to remain competitive. Key players are investing heavily in research and development, with a strong focus on expanding product offerings and gaining first-hand advantages in new cardiac device technologies. 'Boston Scientific Corporation ', 'Medtronic ', 'Edwards Lifesciences Corporation ', 'Abbott Laboratories ', 'St. Jude Medical ', 'Biomerics ', 'Comed BV ', 'LivaNova PLC ', 'JenaValve Technology, Inc. ', 'CardioKinetix ', 'Lepu Medical Technology ', 'CryoLife ', 'Micro Interventional Devices ', 'Braile Biomédica ', 'TTK Healthcare (A TTK Group Company)'

The incidence of heart failure is increasing worldwide due to factors such as aging population, sedentary lifestyle, and poor diet, leading to an increasing demand for cardiac devices, with frequent diagnosis of organized heart failure, such as aortic stenosis, mitral regurgitation, and congenital heart defects in older adults. Advanced cardiac mechanical engineering requirements are likely to perpetuate, with transcatheter intracardiac including veins and occluders. 

Increasing Adoption of Transcatheter Aortic Valve Replacement (TAVR) Systems: Transcatheter aortic valve replacement (TAVR) has become popular as the treatment of choice for patients with severe aortic stenosis, especially those unsuitable for open heart surgery. In clinical trials and ongoing safety studies with the advantages of TAVR, this less penetrating approach continues to increase the demand for structural heart devices will be expected as manufacturers are investing aggressively in next-generation TAVR systems, to expand patients to increase structural heart devices market outlook. 

North America dominated the structural heart devices industry and held the largest revenue share of 40.8% in 2022, due to rising healthcare expenditures, increasing R&D activities, and increasing incidence of heart disease due to growth so in geriatrics. The demand for minimally invasive procedures is also a major reason the region dominates. According to data released by Cedars-Sinai in January 2022, the most common heart surgery is coronary artery bypass graft surgery (CABG)/coronary artery bypass surgery Each year, more than 300,000 patients in the United States undergo surgery prominent. This explains the increasing prevalence of heart disease in the country. 

Request Free Customization

Want to customize this report? This report can be personalized according to your needs. Our analysts and industry experts will work directly with you to understand your requirements and provide you with customized data in a short amount of time. We offer $1000 worth of FREE customization at the time of purchase.

logo-images

Feedback From Our Clients

Global Structural Heart Devices Market

Report ID: SQMIG35G2184

$5,300
BUY NOW GET FREE SAMPLE